KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Capital Expenditures: 2019-2024

Historic Capital Expenditures for AbCellera Biologics (ABCL) over the last 6 years, with Dec 2024 value amounting to $78.4 million.

  • AbCellera Biologics' Capital Expenditures fell 51.78% to $8.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.6 million, marking a year-over-year decrease of 37.10%. This contributed to the annual value of $78.4 million for FY2024, which is 1.88% up from last year.
  • According to the latest figures from FY2024, AbCellera Biologics' Capital Expenditures is $78.4 million, which was up 1.88% from $76.9 million recorded in FY2023.
  • In the past 5 years, AbCellera Biologics' Capital Expenditures registered a high of $78.4 million during FY2024, and its lowest value of $9.7 million during FY2020.
  • In the last 3 years, AbCellera Biologics' Capital Expenditures had a median value of $76.9 million in 2023 and averaged $75.3 million.
  • Data for AbCellera Biologics' Capital Expenditures shows a peak YoY skyrocketed of 504.28% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows AbCellera Biologics' Capital Expenditures stood at $9.7 million in 2020, then skyrocketed by 504.28% to $58.5 million in 2021, then rose by 20.89% to $70.7 million in 2022, then increased by 8.90% to $76.9 million in 2023, then increased by 1.88% to $78.4 million in 2024.